Eupi 40 mg/vial (IV Injection)

40 mg vial: ৳ 80.00

Medicine Details

Category Details
Generic Omeprazole
Company Pharmasia limited
Also available as
Eupi 20 mg capsule Eupi 40 mg capsule

Indications

  • Gastric and duodenal ulcer
  • NSAID-associated duodenal and gastric ulcer
  • As prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
  • Gastro-esophageal reflux disease
  • Long-term management of acid reflux disease
  • Acid-related dyspepsia
  • Severe ulcerating reflux esophagitis
  • Prophylaxis of acid aspiration during general anesthesia
  • Zollinger-Ellison syndrome
  • Helicobacter pylori-induced peptic ulcer

Pharmacology

  • Inhibitor of gastric acid secretion
  • Blocker of hydrogen-potassium-adenosine triphosphatase (H+/K+ ATPase) enzyme system
  • Onset of antisecretory effect within one hour
  • Maximum effect occurring within two hours
  • Inhibition of secretion lasting up to 72 hours
  • Gradual return of secretory activity over 3 to 5 days after discontinuation

Dosage

  • Oral administration
  • Benign gastric and duodenal ulcer dosage regimen
  • NSAID-associated duodenal or gastric ulcer dosage regimen
  • Gastro-esophageal reflux disease dosage regimen
  • Long-term management of acid reflux disease dosage regimen
  • Acid-related dyspepsia dosage regimen
  • Prophylaxis of acid aspiration dosage regimen
  • Zollinger-Ellison syndrome dosage regimen
  • Helicobacter pylori eradication regimen in peptic ulcer disease
  • Pediatric use in severe ulcerating reflux esophagitis dosage regimen
  • IV Injection administration for prophylaxis of acid aspiration, duodenal ulcer, gastric ulcer, or reflux oesophagitis

Administration

  • IV Injection direction and reconstitution process
  • IV Infusion process and reconstitution
  • Use of freshly prepared solution
  • Use within specific time frame after reconstitution
  • Avoidance of mixing or co-administration with other drugs

Interaction

  • Potential impact on ketoconazole absorption
  • Metabolism through cytochrome P450 affecting diazepam, phenytoin, and warfarin
  • Monitoring and potential dose adjustment for warfarin or phenytoin
  • Increased plasma concentrations during concomitant administration with clarithromycin
  • No evidence of interaction with phenacetin, theophylline, caffeine, and other substances
  • Increased bioavailability of digoxin during simultaneous treatment
  • Absorption not affected by alcohol or food

Contraindications

  • Known hypersensitivity to omeprazole
  • Need for exclusion of malignancy in suspected gastric ulcer before treatment

Side Effects

  • Mild and reversible adverse reactions
  • Reported skin rash, urticaria, pruritus, photosensitivity, and bullous eruption
  • Gastrointestinal reactions such as diarrhea, headache, constipation, and nausea/vomiting
  • Neurological reactions including dizziness, somnolence, and paraesthesia
  • Potential mental confusion, agitation, and depression in severely ill patients
  • Musculoskeletal symptoms and rare instances of vision disturbance, gynaecomastia, and hepatic failure

Pregnancy & Lactation

  • No adverse effects indicated on pregnancy or fetal health from epidemiological studies
  • Use during pregnancy deemed safe
  • No available information on passage into breast milk and effects on neonate

Precautions & Warnings

  • Avoid concomitant use with clopidogrel
  • Potential association with increased risk for osteoporosis-related fractures
  • Atrophic gastritis noted in long-term treatment

Therapeutic Class

  • Proton Pump Inhibitor

Storage Conditions

  • Keep in a dry place away from light and heat
  • Keep out of the reach of children

Related Brands